- Home
- SCYX vs XOS Comparison
SCYX vs XOS Comparison
Compare SCYX & XOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- XOS
- Stock Information
- Founded
- SCYX 1999
- XOS 2016
- Country
- SCYX United States
- XOS United States
- Employees
- SCYX N/A
- XOS N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- XOS Construction/Ag Equipment/Trucks
- Sector
- SCYX Health Care
- XOS Consumer Discretionary
- Exchange
- SCYX Nasdaq
- XOS Nasdaq
- Market Cap
- SCYX 28.5M
- XOS 25.6M
- IPO Year
- SCYX 2014
- XOS N/A
- Fundamental
- Price
- SCYX $0.72
- XOS $3.46
- Analyst Decision
- SCYX
- XOS Buy
- Analyst Count
- SCYX 0
- XOS 5
- Target Price
- SCYX N/A
- XOS $8.80
- AVG Volume (30 Days)
- SCYX 200.7K
- XOS 22.4K
- Earning Date
- SCYX 08-07-2025
- XOS 08-13-2025
- Dividend Yield
- SCYX N/A
- XOS N/A
- EPS Growth
- SCYX N/A
- XOS N/A
- EPS
- SCYX N/A
- XOS N/A
- Revenue
- SCYX $2,630,000.00
- XOS $48,678,000.00
- Revenue This Year
- SCYX $410.22
- XOS $1.45
- Revenue Next Year
- SCYX $248.83
- XOS $27.16
- P/E Ratio
- SCYX N/A
- XOS N/A
- Revenue Growth
- SCYX N/A
- XOS N/A
- 52 Week Low
- SCYX $0.66
- XOS $2.73
- 52 Week High
- SCYX $2.28
- XOS $9.15
- Technical
- Relative Strength Index (RSI)
- SCYX 46.77
- XOS 62.25
- Support Level
- SCYX $0.67
- XOS $3.30
- Resistance Level
- SCYX $0.83
- XOS $3.59
- Average True Range (ATR)
- SCYX 0.05
- XOS 0.15
- MACD
- SCYX 0.01
- XOS 0.04
- Stochastic Oscillator
- SCYX 46.35
- XOS 79.65
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About XOS Xos Inc.
Xos Inc is a fleet electrification solutions provider committed to the decarbonization of commercial transportation. Xos designs and manufactures Classes 5 through 8 battery-electric commercial vehicles that travel on last-mile, back-to-base routes of up to 200 miles per day. Xos also offers charging infrastructure products and services through Xos Energy Solutions to support electric vehicle fleets. Its products include Stepvan, MDXT, HDXT, Xosphere, and Xos Energy Solutions.